Page last updated: 2024-10-30

metformin and Epithelial Neoplasms

metformin has been researched along with Epithelial Neoplasms in 10 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect."7.77Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. ( Beauchamp, MC; Gotlieb, WH; Piura, E; Pollak, M; Segal, E; Yasmeen, A, 2011)
"When metformin was combined with carboplatin or paclitaxel, an increased apoptotic activity was observed, implicating a chemo-adjuvant potential."5.42Metformin and epithelial ovarian cancer therapeutics. ( Kumar, L; Patel, S; Singh, N, 2015)
"The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect."3.77Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. ( Beauchamp, MC; Gotlieb, WH; Piura, E; Pollak, M; Segal, E; Yasmeen, A, 2011)
"Metformin has been shown to act in synergy with certain anti-cancer agents, overcoming chemoresistance in various types of tumors."1.48Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. ( Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG, 2018)
"Metformin use was not associated with overall survival in the entire cohort (HR 0."1.46A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer. ( Balkrishnan, R; Camacho, F; Cantrell, LA; Garcia, C; Yao, A, 2017)
"Low-grade serous ovarian cancer (LGSOC) constitutes 5-8% of epithelial ovarian cancers and is refractory to chemotherapy."1.46Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. ( Allo, G; Carey, MS; Chhina, J; Dai, J; Giri, S; Llaurado, M; Mert, I; Munkarah, AR; Rattan, R; Seward, S, 2017)
"BRCA mutated ovarian cancers show increased responsiveness to PARP inhibitors."1.43Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. ( Al-Wahab, Z; Ali-Fehmi, R; Buekers, T; Chhina, J; Dar, S; Hijaz, M; Mert, I; Munkarah, AR; Rattan, R; Taylor, M, 2016)
"When metformin was combined with carboplatin or paclitaxel, an increased apoptotic activity was observed, implicating a chemo-adjuvant potential."1.42Metformin and epithelial ovarian cancer therapeutics. ( Kumar, L; Patel, S; Singh, N, 2015)
"The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen‑activated protein kinase (MAPK) inhibitor, on the sensitivity of cisplatin‑resistant ovarian cancer to cisplatin."1.40Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer. ( Guo, H; Ji, M; Peng, Z; Shi, H; Shi, M; Xie, Y, 2014)
"This association is less clear in epithelial ovarian cancer (EOC)."1.40Diabetes mellitus and ovarian cancer: more complex than just increasing risk. ( Daily, LB; Erickson, BK; Fauci, JM; Haygood, CW; Leath, CA; Martin, JY; Matin, T; McGwin, G; Pasko, D; Shah, MM, 2014)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Garcia, C1
Yao, A1
Camacho, F1
Balkrishnan, R1
Cantrell, LA1
Mert, I2
Chhina, J2
Allo, G1
Dai, J1
Seward, S1
Carey, MS1
Llaurado, M1
Giri, S2
Rattan, R3
Munkarah, AR2
Dos Santos Guimarães, I1
Ladislau-Magescky, T1
Tessarollo, NG1
Dos Santos, DZ1
Gimba, ERP1
Sternberg, C1
Silva, IV1
Rangel, LBA1
Holzgreve, H1
Xie, Y1
Peng, Z1
Shi, M1
Ji, M1
Guo, H1
Shi, H1
Shah, MM1
Erickson, BK1
Matin, T1
McGwin, G1
Martin, JY1
Daily, LB1
Pasko, D1
Haygood, CW1
Fauci, JM1
Leath, CA1
Patel, S1
Kumar, L1
Singh, N1
Hijaz, M1
Taylor, M1
Dar, S1
Al-Wahab, Z1
Ali-Fehmi, R1
Buekers, T1
Yasmeen, A1
Beauchamp, MC1
Piura, E1
Segal, E1
Pollak, M1
Gotlieb, WH1
Kumar, S1
Meuter, A1
Thapa, P1
Langstraat, C1
Chien, J1
Cliby, W1
Shridhar, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024]Phase 250 participants (Anticipated)Interventional2015-03-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

10 other studies available for metformin and Epithelial Neoplasms

ArticleYear
A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecologic oncology, 2017, Volume: 146, Issue:2

    Topics: Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Cohort Studies; Female; Humans; Hypoglycemic

2017
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Gynecologic oncology, 2017, Volume: 146, Issue:2

    Topics: AMP-Activated Protein Kinases; Antimetabolites; Blotting, Western; Carcinoma, Ovarian Epithelial; Ce

2017
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferati

2018
[Not Available].
    MMW Fortschritte der Medizin, 2013, May-29, Volume: 155, Issue:10

    Topics: Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms

2013
Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.
    Molecular medicine reports, 2014, Volume: 10, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplati

2014
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
    Gynecologic oncology, 2014, Volume: 135, Issue:2

    Topics: Adenocarcinoma, Papillary; Aged; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Comorbidity

2014
Metformin and epithelial ovarian cancer therapeutics.
    Cellular oncology (Dordrecht), 2015, Volume: 38, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carb

2015
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Gynecologic oncology, 2016, Volume: 142, Issue:2

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protei

2016
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
    Gynecologic oncology, 2011, Jun-01, Volume: 121, Issue:3

    Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Car

2011
Metformin intake is associated with better survival in ovarian cancer: a case-control study.
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cohort Studies; Di

2013
chemdatabank.com